Health Care & Life Sciences » Pharmaceuticals | Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc. | Ownership

Companies that own Aeglea BioTherapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Nantahala Capital Management LLC
2,213,052
10.06%
368,379
1.74%
06/30/2018
OrbiMed Advisors LLC
1,865,524
8.48%
396,000
0.21%
06/30/2018
Jennison Associates LLC
1,525,447
6.94%
20,349
0.01%
06/30/2018
Baker Bros. Advisors LP
1,387,872
6.31%
250,000
0.1%
06/30/2018
Adage Capital Management LP
890,702
4.05%
640,702
0.02%
06/30/2018
BlackRock Fund Advisors
741,390
3.37%
718,414
0%
06/30/2018
The Vanguard Group, Inc.
666,353
3.03%
332,130
0%
06/30/2018
Rock Springs Capital Management LP
650,000
2.96%
125,911
0.26%
06/30/2018
Renaissance Technologies LLC
528,200
2.4%
426,200
0.01%
06/30/2018
Sphera Funds Management Ltd.
509,118
2.31%
509,118
0.81%
06/30/2018

About Aeglea BioTherapeutics

View Profile
Address
Barton Oaks Plaza One
Austin Texas 78746
United States
Employees -
Website http://www.aegleabio.com
Updated 07/08/2019
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.